Document


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K

 
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): June 2, 2016
 

Natus Medical Incorporated
(Exact name of registrant as specified in its charter)


 
Delaware
 
000-33001
 
77-0154833
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
6701 Koll Center Parkway Suite 120 Pleasanton, CA 94566
(Address of principal executive offices)    (Zip Code)

Registrant’s telephone number, including area code: (925) 223-6700
 
Not applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 





 
ITEM 5.07.
Submission of Matters to a Vote of Security Holders
 
On June 2, 2016, Natus Medical Incorporated (the “Company”) held its annual meeting of stockholders. At this meeting, James B. Hawkins and Robert A. Gunst were re-elected to serve on the Board of Directors for a three-year term until 2019. Additionally, shareholders ratified the appointment of KPMG as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016, provided advisory approval of the Company’s named executive officer compensation.
 
Proposal 1: Election of Directors
 
Nominee
 
 
 
 
 
 
 
 
For
 
Against
 
Abstain
 
Broker
Non-Votes
James B. Hawkins
25,910,812
 
1,320,573
 
7,039
 
3,984,304
Robert A. Gunst
26,237,720
 
993,107
 
7,597
 
3,984,304
 
Proposal 2: Ratification of KPMG as Auditors
 
For
 
Against
 
Abstain
 
 
 
31,167,568
 
23,436
 
31,724
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proposal 3:  Advisory Approval of the Company’s Executive Compensation
 
 
For
 
Against
 
Abstain
 
Broker
Non-Votes
 
25,569,547
 
1,543,030
 
125,847
 
3,984,304
 
 
 
 
 
 
 
 
 
No other matters were considered or voted upon at the meeting.
 
 
 

 
SIGNATURES

 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NATUS MEDICAL INCORPORATED
 
 
 
 
Date: June 3, 2016
 
 
 
By:
 
/s/ Jonathan A. Kennedy
 
 
 
 
 
 
Jonathan A. Kennedy
 
 
 
 
 
 
Senior Vice President Finance & Chief Financial Officer